Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease.Graft-versus-host disease (GvHD) often occurs after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient’s body. The condition is often associated with treatment [...]

Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most recent quarterly earnings call.Van Bokkelen said Cleveland-based Athersys’ MultiStem stem cell therapy for ischemic stroke “could easily be one of the biggest blockbusters that the [...]

As the basketball frenzy that accompanies March Madness draws to the fever pitch of the Final Four, it brings to mind that basketball is a high contact sport. A quick peek at the NBA injured list reveals a catalog of breaks and tears that affect tendons, ligaments and bones.The pressure to improve performance and search [...]

The head of a stem cell company has responded to a warning letter issued by the U.S. Food and Drug Administration that cites several violations at the company that derives stem cells from adipose tissue or body fat.Dr. Steven Victor of IntelliCell BioSciences said it would be moving to a new facility next month that [...]

A warning letter issued by the U.S. Food and Drug Administration has cited numerous violations by a stem cell company and claimed it did not have an appropriate license to produce stem cells.IntelliCell BioSciences in New York derives stem cells from adipose tissue, or fat cells, for treatments ranging from lower back pain to cosmetic [...]

Regenerative medicine startup Juventas Therapeutics is planning to begin enrollment in a phase 2 heart failure clinical trial next quarter.The Cleveland-based company’s technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels and prevent ongoing cell death at the site of a patient’s injury.During the trial, Juventas will deliver [...]

Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor.Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal number of warrants to purchase common shares at a price of $2.07. The warrants are exercisable for five years, according to a statement [...]

Cytomedix‘s (OTC:CMXI) Aldagen acquisition signaled the company’s intention to establish a strong presence in regenerative medicine therapies and the deal fills needs for both companies. Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective [...]

Regenerative medicine company Cytomedix (OTC:CMXI) has acquired North Carolina stem cell technology company Aldagen in a stock deal valued at $40 million that broadens the firm’s regenerative therapies pipeline.Maryland-based Cytomedix develops biologically active regenerative therapies for wound care, inflammation and blood vessel development. The company has been diversifying to build its regenerative medicine capabilities. Aldagen’s [...]

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases.The trial showed that the company’s MultiStem technology may reduce the incidence and severity of graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem cell [...]